Literature DB >> 20506512

Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study.

Karim Sacré1, Benoit Brihaye, Fabien Hyafil, Jean-Michel Serfaty, Brigitte Escoubet, Maria-Christina Zennaro, Olivier Lidove, Jean-Pierre Laissy, Thomas Papo.   

Abstract

OBJECTIVE: Antiphospholipid syndrome (APS) may cause coronary thrombosis. This study was undertaken to determine the prevalence of silent myocardial disease in patients with APS, using late gadolinium enhancement (LGE) of cardiac magnetic resonance imaging (CMRI).
METHODS: Twenty-seven consecutive patients with APS and 81 control subjects without known cardiovascular disease underwent CMRI. The prevalence of occult myocardial ischemic disease, as revealed by LGE, was compared between patients with APS and controls, and factors associated with myocardial disease were identified in patients with APS.
RESULTS: Myocardial ischemic disease, as characterized by LGE on CMRI, was present in 8 (29.6%) of 27 patients with APS, and imaging with LGE showed a typical pattern of myocardial infarction (MI) in 3 patients (11.1%). The myocardial scarring revealed on CMRI was not detected by electrocardiography or echocardiography. Although both patients with APS and control subjects shared a low risk of cardiovascular events, as calculated with the Framingham risk equation (mean +/- SD 5.1 +/- 8.2% and 6.5 +/- 7.6%, respectively, for the absolute risk within the next 10 years; P = 0.932), the prevalence of myocardial ischemia was more than 7 times higher in patients with APS (P = 0.0006 versus controls). No association was found between myocardial disease in patients with APS and classic coronary risk factors. The presence of myocardial scarring tended to be more closely associated with specific features of APS, such as duration of the disease, presence of livedo, and positivity for anti-beta(2)-glycoprotein I antibodies.
CONCLUSION: The finding of a significant and unexpectedly high prevalence of occult myocardial scarring in patients with APS indicates the usefulness of CMRI with LGE for the identification of silent myocardial disease in such patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20506512     DOI: 10.1002/art.27488

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

2.  Cardiovascular Considerations in Anesthetic Management for a Patient With Antiphospholipid Syndrome and Decreased Cardiac Function: A Case Study.

Authors:  Makiko Shibuya; Yukifumi Kimura; Shigeru Takuma; Nobuhito Kamekura Dds; Toshiaki Fujisawa
Journal:  Anesth Prog       Date:  2021-03-01

3.  Risk Factors and Outcomes of Acute Myocardial Infarction in a Cohort of Antiphospholipid Syndrome.

Authors:  Yuzhou Gan; Yawei Zhao; Gongming Li; Hua Ye; Yunshan Zhou; Chang Hou; Lan Wang; Jianping Guo; Chun Li
Journal:  Front Cardiovasc Med       Date:  2022-07-05

Review 4.  The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.

Authors:  J Michelle Kahlenberg; Mariana J Kaplan
Journal:  Arthritis Res Ther       Date:  2011-02-28       Impact factor: 5.156

Review 5.  Cardiovascular risk factors in the antiphospholipid syndrome.

Authors:  Felipe Freire da Silva; Roger Abramino Levy; Jozélio Freire de Carvalho
Journal:  J Immunol Res       Date:  2014-07-13       Impact factor: 4.818

6.  Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.

Authors:  Enrico Ammirati; Emanuele Bizzi; Giacomo Veronese; Matthieu Groh; Caroline M Van de Heyning; Jukka Lehtonen; Marc Pineton de Chambrun; Alberto Cereda; Chiara Picchi; Lucia Trotta; Javid J Moslehi; Antonio Brucato
Journal:  Front Med (Lausanne)       Date:  2022-03-07

7.  Primary Antiphospholipid Syndrome with and Without Acute Myocardial Infarction/Angina: A Cross-Sectional Study.

Authors:  Jozélio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Ther       Date:  2022-01-09

Review 8.  Cardiac Magnetic Resonance in Rheumatology to Detect Cardiac Involvement Since Early and Pre-clinical Stages of the Autoimmune Diseases: A Narrative Review.

Authors:  Lilia M Sierra-Galan; Mona Bhatia; Angel Leovigildo Alberto-Delgado; Javier Madrazo-Shiordia; Carlos Salcido; Bernardo Santoyo; Eduardo Martinez; Maria Elena Soto
Journal:  Front Cardiovasc Med       Date:  2022-07-13

9.  Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome.

Authors:  Maria G Tektonidou; Petros P Sfikakis; Genovefa Kolovou; Sophie Mavrogeni
Journal:  Mediterr J Rheumatol       Date:  2018-06-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.